Neurology&Stroke Dpt, St. Adalbert Hospital, Gdańsk, Poland.
Neurology&Stroke Dpt, St. Adalbert Hospital, Gdańsk, Poland.
Parkinsonism Relat Disord. 2023 Jan;106:105238. doi: 10.1016/j.parkreldis.2022.105238. Epub 2022 Dec 6.
After more than 2 years of the pandemic, effective treatment for COVID-19 is still under research. In recent months, publications hypothesized amantadine's potential beneficial effect on SARS-CoV-2 infection.
To compare the groups of Parkinson's Disease (PD) patients who were administered amantadine chronically and those who did not take this medication in the context of the incidence and severity of COVID-19 infection.
An observational, retrospective, multicenter cohort study was conducted among consecutive patients with idiopathic PD. The structured questionnaires were completed during the patient's follow-up visits at the Outpatient Clinic or during hospitalization. The questionnaire included the following informations: patient's age, duration of PD, Hoehn-Yahr (H-Y) stage, comorbidities, medications, COVID-19 confirmed by reverse transcription polymerase chain reaction (RT-PCR) swab test for SARS-CoV-2 with specified symptoms and their severity (home or hospital treatment). The vaccination status was verified as well.
Five hundred fifty-two (n = 552) patients participated in the study - 329 men (60%). The mean H-Y stage was 2.44 (range: 1-4) and the mean duration of PD was 9.6 years (range: 1-34). One hundred four subjects (19%) had confirmed COVID-19 infection. Subjects over 50 years of age had a significantly lower incidence of COVID-19 (17% vs 38%, p = 0.0001) with difference also in mean H-Y stage (2.27 vs 2.49; p = 0.011) and disease duration (8.4 vs 9.9 years, p = 0.007). There were no differences between patients with and without co-morbidities. In the whole analyzed group 219 (40%) subjects were treated with amantadine. Comparing COVID-19 positive and negative patients, amantadine was used by 48/104 (46%) and 171/448 (38%) respectively. 22% of patients on amantadine vs. 17% of patients without amantadine developed COVID-19. These differences were not significant. There were no differences in morbidity and severity of COVID-19 between amantadine users and non-users as well.
COVID-19 was less common in older (>50) with longer duration and more advanced patients. Amantadine did not affect the risk of developing COVID-19 or the severity of infection.
在大流行超过 2 年后，COVID-19 的有效治疗方法仍在研究中。最近几个月，有出版物假设金刚烷胺对 SARS-CoV-2 感染可能具有有益作用。
比较长期服用金刚烷胺和未服用金刚烷胺的帕金森病（PD）患者在 COVID-19 感染的发生率和严重程度方面的差异。
对特发性 PD 连续患者进行了一项观察性、回顾性、多中心队列研究。在门诊就诊或住院期间，通过结构化问卷完成了患者的随访。问卷包括以下信息：患者年龄、PD 病程、Hoehn-Yahr（H-Y）分期、合并症、药物治疗、COVID-19 通过逆转录聚合酶链反应（RT-PCR）拭子检测 SARS-CoV-2 确诊，伴有规定的症状及其严重程度（在家或住院治疗）。还验证了疫苗接种情况。
552 名患者（n=552）参与了研究，其中 329 名男性（60%）。平均 H-Y 分期为 2.44（范围：1-4），PD 病程平均为 9.6 年（范围：1-34）。104 名患者（19%）确诊 COVID-19 感染。50 岁以上患者 COVID-19 发病率显著降低（17% vs 38%，p=0.0001），H-Y 分期（2.27 vs 2.49；p=0.011）和病程（8.4 岁 vs 9.9 岁，p=0.007）也有差异。合并症患者与无合并症患者之间无差异。在整个分析组中，219 名（40%）患者接受了金刚烷胺治疗。在 COVID-19 阳性和阴性患者中，分别有 48/104（46%）和 171/448（38%）患者使用了金刚烷胺。金刚烷胺组 22%的患者 vs. 无金刚烷胺组 17%的患者发生 COVID-19。这些差异无统计学意义。金刚烷胺使用者和非使用者 COVID-19 的发病率和严重程度也无差异。
年龄较大（>50 岁）、病程较长和病情较重的患者 COVID-19 较少见。金刚烷胺不会影响发生 COVID-19 或感染严重程度的风险。
Zotero 插件